Researchers have proposed a unifying mathematical framework that helps explain why many successful multimodal AI systems work ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research ...

Vancouver firm's AI platform will generate chemical compounds based on Merck’s therapeutic targets. A Vancouver startup using artificial intelligence (AI) to discover new drugs has struck a deal with ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...

VANCOUVER, British Columbia, September 23, 2025--(BUSINESS WIRE)--Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the ...

Generating synthetic data is useful when you have imbalanced training data for a particular class, for example, generating synthetic females in a dataset of employees that has many males but few ...

Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that ...